Kymriah (Tisagenlecleucel)

Tisagenlecleucel is an autologous CAR T‑cell product. A patient’s T cells are collected, genetically modified to express a chimeric antigen receptor that binds CD19 on B‑cells, expanded, and then infused back. The engineered cells locate and destroy CD19‑expressing cancer cells while persisting to provide ongoing immune surveillance.

The dose of Kymriah is individualized. The prescribing physician determines the cell dose based on the patient’s weight, disease characteristics, and manufacturing specifications. No fixed dosing schedule is provided in public materials.

The safety of Kymriah in pregnancy or while breastfeeding has not been established. Because it involves live cellular therapy, clinicians generally advise avoiding use in pregnant or nursing individuals unless the potential benefit justifies the potential risk.

To request Kymriah, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Kymriah is a CD19‑directed autologous CAR T‑cell therapy approved for specific B‑cell malignancies. Compared with other products, it uses a 4‑1BB co‑stimulatory domain, which may influence persistence and toxicity profile. Clinical outcomes and safety differ among products, so selection depends on regulatory approval, disease indication, and patient factors.

Kymriah must be stored refrigerated at 2‑8 °C. The product should be kept in its original container, protected from light, and must not be frozen or shaken. Handling follows strict cold‑chain procedures to maintain cell viability.

Kymriah is delivered as a cell suspension for intravenous infusion. After the manufacturing process, the product is thawed, washed, and infused over a short period under close medical supervision, typically in a specialized oncology or transplant centre equipped for cellular therapy.

The most serious risks include cytokine release syndrome, severe neurotoxicity (ICANS), tumor lysis syndrome, prolonged cytopenias, B‑cell aplasia with resultant hypogammaglobulinemia, and opportunistic infections. Early detection and prompt management are essential to mitigate these complications.

Patients who lack CD19 expression on their malignant cells, those with active uncontrolled infections, or individuals who have received other CAR T‑cell products or certain immunosuppressive therapies shortly before infusion may be unsuitable. Final eligibility is determined by the treating physician based on clinical guidelines.